What one share of Rapport Therapeutics holds
We are a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders. Our foundational science has elucidated the complexities of neuronal receptor biology and enables us to map and target certain neuronal receptor complexes.
Rapport Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.06 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.16 |
| Cash and investments | $1.33 |
| Book value | $8.82 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$23.10 | $1.09 | −$19.14 | — | — |
| 2024 | — | −$3.78 | $0.12 | −$3.24 | — | $8.35 |
| 2025 | — | −$2.86 | $0.02 | −$2.26 | — | $10.14 |
Common questions about Rapport Therapeutics
How much does one share of Rapport Therapeutics earn?
Over the last 12 months, Rapport Therapeutics lost $3.06 for each share.
Does Rapport Therapeutics pay a dividend?
Rapport Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Rapport Therapeutics’s book value per share?
Rapport Therapeutics’s book value is $8.82 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Rapport Therapeutics have?
Each share of Rapport Therapeutics has $1.33 of cash and investments, as of June 30, 2026.
What is Rapport Therapeutics’s free cash flow per share?
−$2.16 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.